Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 5Breast Neoplasms 5Pancreatic Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Hematologic Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

spartalizumab 2pembrolizumab 2trastuzumab deruxtecan 1trametinib 1siremadlin 1sargramostim 1resiquimod 1poly ICLC 1pegfilgrastim 1nazartinib 1liposomal doxorubicin 1lenvatinib 1eribulin 1enzalutamide 1canakinumab 1Vaccines 1TKM-080301 1Quality of Life 1Prednisone 1Prednisolone 1Patient Reported Outcome Measures 1Panobinostat 1Molecular Diagnostic Techniques 1MORAb-202 1LCL161 1Ipilimumab 1Immunotherapy 1Imatinib Mesylate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × trametinib × Breast × Clear all
NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔